CN106687464B - 大环rip2激酶抑制剂 - Google Patents

大环rip2激酶抑制剂 Download PDF

Info

Publication number
CN106687464B
CN106687464B CN201580050163.3A CN201580050163A CN106687464B CN 106687464 B CN106687464 B CN 106687464B CN 201580050163 A CN201580050163 A CN 201580050163A CN 106687464 B CN106687464 B CN 106687464B
Authority
CN
China
Prior art keywords
alkyl
het
halogen
independently
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580050163.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106687464A (zh
Inventor
J·霍夫拉克
P·布罗姆
P·本德里特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncodisen Precision Pharmaceutical Opm
Original Assignee
ONCODESIGN SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ONCODESIGN SA filed Critical ONCODESIGN SA
Publication of CN106687464A publication Critical patent/CN106687464A/zh
Application granted granted Critical
Publication of CN106687464B publication Critical patent/CN106687464B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580050163.3A 2014-09-17 2015-09-17 大环rip2激酶抑制剂 Active CN106687464B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185130 2014-09-17
EP14185130.3 2014-09-17
PCT/EP2015/071347 WO2016042087A1 (en) 2014-09-17 2015-09-17 Macrocyclic rip2 kinase inhibitors

Publications (2)

Publication Number Publication Date
CN106687464A CN106687464A (zh) 2017-05-17
CN106687464B true CN106687464B (zh) 2020-03-03

Family

ID=51687776

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580050163.3A Active CN106687464B (zh) 2014-09-17 2015-09-17 大环rip2激酶抑制剂

Country Status (26)

Country Link
US (1) US10676486B2 (enExample)
EP (1) EP3194407B1 (enExample)
JP (1) JP6736545B2 (enExample)
KR (1) KR102563829B1 (enExample)
CN (1) CN106687464B (enExample)
AU (1) AU2015316799B2 (enExample)
BR (1) BR112017004035B1 (enExample)
CA (1) CA2958782C (enExample)
DK (1) DK3194407T3 (enExample)
EA (1) EA032872B1 (enExample)
ES (1) ES2763344T3 (enExample)
HR (1) HRP20192334T1 (enExample)
HU (1) HUE048518T2 (enExample)
IL (1) IL250544B (enExample)
LT (1) LT3194407T (enExample)
MX (1) MX376087B (enExample)
MY (1) MY186523A (enExample)
PL (1) PL3194407T3 (enExample)
PT (1) PT3194407T (enExample)
SA (1) SA517381087B1 (enExample)
SG (1) SG11201701116XA (enExample)
SI (1) SI3194407T1 (enExample)
TW (1) TWI709563B (enExample)
UA (1) UA121315C2 (enExample)
WO (1) WO2016042087A1 (enExample)
ZA (1) ZA201701331B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102719387B1 (ko) * 2017-01-26 2024-10-21 한미약품 주식회사 이미다조피리다진 화합물
UY39061A (es) 2020-01-31 2022-01-31 Oncodesign Sa Inhibidores macrocíclicos de rip2-cinasa
CN117659043A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
WO2024146541A1 (en) * 2023-01-03 2024-07-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Macrocyclic compounds as usp1 inhibitors
WO2025212514A2 (en) * 2024-04-02 2025-10-09 Interline Therapeutics, Inc. Methods of treating inflammatory diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600718A (zh) * 2006-11-06 2009-12-09 休普基因公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
CN102596957A (zh) * 2009-07-09 2012-07-18 阵列生物制药公司 作为TRK激酶抑制剂的被取代的吡唑并[1,5-a]嘧啶化合物
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CN103930427A (zh) * 2011-09-30 2014-07-16 昂科迪塞恩股份有限公司 大环flt3 激酶抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ES2166786T3 (es) 1993-10-01 2002-05-01 Astrazeneca Ab Procedimiento i.
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
EP2760453B1 (en) 2011-09-30 2016-05-25 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600718A (zh) * 2006-11-06 2009-12-09 休普基因公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
CN102596957A (zh) * 2009-07-09 2012-07-18 阵列生物制药公司 作为TRK激酶抑制剂的被取代的吡唑并[1,5-a]嘧啶化合物
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
CN103930427A (zh) * 2011-09-30 2014-07-16 昂科迪塞恩股份有限公司 大环flt3 激酶抑制剂

Also Published As

Publication number Publication date
CA2958782A1 (en) 2016-03-24
CA2958782C (en) 2024-01-09
HRP20192334T1 (hr) 2020-03-20
BR112017004035A8 (pt) 2023-05-09
KR20170048596A (ko) 2017-05-08
UA121315C2 (uk) 2020-05-12
MX2017003469A (es) 2017-05-08
SI3194407T1 (sl) 2020-03-31
SG11201701116XA (en) 2017-03-30
HUE048518T2 (hu) 2020-07-28
US20190127390A1 (en) 2019-05-02
AU2015316799A1 (en) 2017-04-27
ZA201701331B (en) 2020-07-29
EP3194407A1 (en) 2017-07-26
IL250544B (en) 2020-06-30
BR112017004035A2 (pt) 2017-12-05
KR102563829B1 (ko) 2023-08-03
ES2763344T3 (es) 2020-05-28
MY186523A (en) 2021-07-24
DK3194407T3 (da) 2020-01-27
MX376087B (es) 2025-03-07
WO2016042087A1 (en) 2016-03-24
EA201790609A1 (ru) 2017-07-31
IL250544A0 (en) 2017-03-30
BR112017004035B1 (pt) 2023-11-14
TW201619168A (zh) 2016-06-01
PT3194407T (pt) 2020-01-20
SA517381087B1 (ar) 2021-02-09
PL3194407T3 (pl) 2020-04-30
JP2017528481A (ja) 2017-09-28
CN106687464A (zh) 2017-05-17
US10676486B2 (en) 2020-06-09
EA032872B1 (ru) 2019-07-31
EP3194407B1 (en) 2019-10-23
JP6736545B2 (ja) 2020-08-05
NZ730758A (en) 2023-09-29
AU2015316799B2 (en) 2019-07-11
TWI709563B (zh) 2020-11-11
LT3194407T (lt) 2020-01-27

Similar Documents

Publication Publication Date Title
JP7675777B2 (ja) 免疫調節剤としての複素環式化合物
KR101974793B1 (ko) Cot 조정제 및 그의 사용 방법
KR101541086B1 (ko) 피롤로피리미딘 화합물 및 그 용도
US20240239785A1 (en) Substituted 2-(2,6-dioxopiperidin-3-yl)-5-(1-piperidin-4-yl)isoindoline-1,3-dione derivatives and uses thereof
CN105308036A (zh) 用于激酶调节的化合物和方法及其适应症
CN105228625A (zh) 大环rip2激酶抑制剂
CN106687464B (zh) 大环rip2激酶抑制剂
CN105209040A (zh) 大环的盐可诱导的激酶抑制剂
CN115504980A (zh) 嘧啶并含氮六元芳香杂环类化合物及其用途
AU2020386189A1 (en) Adenosine receptor antagonist compounds
WO2014181813A1 (ja) 複素環化合物
CN110078743A (zh) 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
TWI889173B (zh) 含苯基取代的二氫萘啶類化合物的藥物製劑與用途
HK1232862B (zh) 大环rip2激酶抑制剂
HK1232862A1 (en) Macrocyclic rip2 kinase inhibitors
WO2023083373A1 (zh) 作为Src抑制剂的化合物
WO2019120256A1 (zh) 五元杂芳环衍生物、其药物组合物及应用
EP2968325A1 (en) Macrocyclic rip2 kinase inhibitors
NZ730758B2 (en) Macrocyclic rip2 kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1232862

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230111

Address after: Dijon

Patentee after: Oncodisen Precision Pharmaceutical (OPM)

Address before: Dijon

Patentee before: ONCODESIGN S.A.